Latest market price
19.74
+0.13+0.66%
TA
Loading chart...
Snapshot
| Index | — | P/E | 75.92 | EPS (ttm) | 0.26 | Insider Own | 1.83% | Shs Outstand | 255.46M | Perf Week | 0.92% |
| Market Cap | 5.04B | Forward P/E | 26.31 | EPS next Y | 0.75 | Insider Trans | -4.28% | Shs Float | 250.79M | Perf Month | 2.81% |
| Enterprise Value | 7.46B | PEG | — | EPS next Q | 0.16 | Short Float | 7.07% | Perf Quarter | -4.22% | ||
| Income | 66.00M | P/S | 5.86 | EPS this Y | -42.67% | Short Ratio | 6.92 | Perf Half Y | -3.05% | ||
| Sales | 860.00M | P/B | 1.83 | EPS next Y | 87.92% | ROA | 1.19% | Short Interest | 17.72M | Perf YTD | 4.22% |
| Book/sh | 10.77 | P/C | 21.74 | EPS next 5Y | — | ROE | 2.34% | 52W High | 22.77 -13.31% | Perf Year | 14.57% |
| Cash/sh | 0.91 | P/FCF | 14.57 | EPS past 3/5Y | — -0.91% | ROIC | 29.10% | 52W Low | 17.25 14.43% | Perf 3Y | 39.51% |
| Dividend Est. | 1.20 (6.08%) | EV/EBITDA | 19.07 | Sales past 3/5Y | 7.43% 5.29% | Gross Margin | 61.84% | Volatility | 2.09% 2.12% | Perf 5Y | 31.25% |
| Dividend TTM | 1.20 (6.08%) | EV/Sales | 8.67 | EPS Y/Y TTM | -65.47% | Oper. Margin | 15.31% | ATR (14) | 0.44 | Perf 10Y | -19.16% |
| Dividend Ex-Date | Aug 14, 2026 | Quick Ratio | 43.68 | Sales Y/Y TTM | 17.33% | Profit Margin | 7.61% | RSI (14) | 53.64 | Recom | 2.69 |
| Dividend Gr. 3/5Y | 0.00% -2.33% | Current Ratio | 43.68 | EPS Q/Q | -135.71% | SMA20 | 2.48% | Beta | 0.65 | Target Price | 21.86 |
| Payout | 455.46% | Debt/Eq | 0.96 | Sales Q/Q | 24.87% | SMA50 | -0.66% | Rel Volume | 0.85 | Prev Close | 19.61 |
| Employees | 58 | LT Debt/Eq | 0.96 | Earnings | Nov 02 | SMA200 | -1.15% | Avg Volume | 2.36M | Price | 19.74 |
| IPO Date | Apr 02, 2002 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -158.45% 7.51% | Net Debt/EBITDA | 6.17 | Volume | 2,015,573 | Change | 0.66% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-13-26 | Reiterated | UBS | Neutral | $25 → $20 |
| Aug-31-26 | Reiterated | Mizuho Securities | Neutral | $20 → $21 |
| Aug-31-26 | Reiterated | Barclays | Equal Weight | $21 → $23 |
| Aug-06-26 | Upgrade | Raymond James | Underperform → Market Perform | |
| Jul-22-26 | Reiterated | UBS | Neutral | $22 → $25 |
| Jul-22-26 | Reiterated | Robert W. Baird | $22 → $23 | |
| Jul-08-26 | Upgrade | Truist Securities | Hold → Buy | $21 → $22 |
| Jul-07-26 | Reiterated | Barclays | Equal Weight | $21 |
| Jun-23-26 | Downgrade | Citigroup | Buy → Neutral | |
| Jun-18-26 | Reiterated | UBS | Neutral | $22 → $19 |
Latest News· Times ET
Oct-26-26
Oct-24-26
Oct-24-2607:15AM
Oct-20-26
Oct-19-26
Oct-19-2604:05PM
07:59AM
Oct-13-26
Sep-26-26
Sep-26-2603:30AM
Sep-25-26
Sep-25-2604:46AM
04:01AM
Sep-21-26
Sep-21-2604:06AM
Sep-15-26
Sep-15-2607:40PM
04:48AM
Sep-10-26
Sep-09-26
Sep-09-2609:05AM
Aug-31-26
Aug-31-2604:52AM
Company
Sabra Health Care REIT, Inc. engages in the business of acquiring, financing, and owning real estate property. The company was founded on May 10, 2010 and is headquartered in Tustin, CA.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 860 | 775 | 703 | 648 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 328 | 271 | 227 | 195 | — | — | — | — | — | |
| Gross Profit | 531 | 504 | 476 | 452 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 61 | 54 | 50 | 47 | — | — | — | — | — | |
| Research and Development | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Other Operating Expense | 340 | 186 | 169 | 184 | — | — | — | — | — | |
| Operating Income | 132 | 264 | 257 | 222 | — | — | — | — | — | |
| Interest Expense | 118 | 112 | 115 | 113 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 51 | 6 | -14 | -93 | — | — | — | — | — | |
| Net Income Before Taxes | 65 | 157 | 128 | 16 | — | — | — | — | — | |
| Income Taxes | 2 | 2 | 1 | 2 | — | — | — | — | — | |
| Consolidated Net Income | 66 | 156 | 127 | 14 | — | — | — | — | — | |
| Net Income From Continuing Operations | 64 | 156 | 127 | 14 | — | — | — | — | — | |
| Net Income | 66 | 156 | 127 | 14 | — | — | — | — | — | |
| EPS (Recurring) | 0.26 | 0.64 | 0.54 | 0.06 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 0.26 | 0.64 | 0.54 | 0.06 | — | — | — | — | — | |
| EPS (Diluted) | 0.26 | 0.64 | 0.54 | 0.06 | — | — | — | — | — | |
| EBITDA | 391 | 457 | 413 | 312 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 75.92 | 29.59 | 32.07 | 241.46 | — | — | — | — | — | |
| Price To Sales Ratio | 5.78 | 5.89 | 5.74 | 5.09 | — | — | — | — | — | |
| Gross Margin | 61.74 | 65.03 | 67.71 | 69.75 | — | — | — | — | — | |
| Operating Margin | 15.35 | 34.06 | 36.56 | 34.26 | — | — | — | — | — | |
| Net Margin | 7.67 | 20.13 | 18.07 | 2.16 | — | — | — | — | — | |
| Shares Outstanding | 252 | 241 | 233 | 231 | — | — | — | — | — | |
| Market Capitalization | 4,974 | 4,565 | 4,036 | 3,296 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| MATROS RICHARD K | Chair, CEO and President | Sep 08 '26 | Sale | 20.83 | 200,000 | 4,166,000 | 1,657,686 | Sep 09 |
| FLORES JESSICA | Executive VP & CAO | Mar 25 '26 | Sale | 19.86 | 15,231 | 302,488 | 71,709 | Mar 26 |
| FOSTER MICHAEL J | Director | May 20 '25 | Sale | 18.22 | 11,000 | 200,376 | 64,725 | May 22 |
| Cusack Catherine | Director | Feb 24 '25 | Buy | 15.92 | 1,500 | 23,880 | 60,583 | Feb 25 |
| Cusack Catherine | Director | Feb 21 '25 | Buy | 16.43 | 1,000 | 16,435 | 59,083 | Feb 25 |
| Cusack Catherine | Director | May 22 '24 | Buy | 14.43 | 7,000 | 101,010 | 46,385 | May 23 |
| FOSTER MICHAEL J | Director | May 14 '24 | Sale | 14.68 | 10,000 | 146,830 | 63,923 | May 17 |
| Costa Michael Lourenco | Executive VP, CFO & Secretary | Sep 01 '23 | Buy | 12.63 | 1,947 | 24,591 | 183,218 | Sep 05 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.